(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Utilize Open Record Rewards for Your Potential benefit - 2Instructions to Really Oversee Unsold SUVs in the Auto Business
- 3Figure out How to Store Your Gold Ventures: A Thorough Aide safely
- 4Putin says Russian forces will seize capital of Zaporizhzhya
- 5American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- Toilet rats? Washington health officials warn of possible rodents in sewer systems after floods
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- What's A Decent FICO rating?
- Gulf of Mexico oil spill spread hundreds of miles, killed wildlife and polluted Mexican reserves
- Lift Your Style: Famous Hairdos for Ladies
- Air Force made critical errors during October 7 massacre, investigator says
- Report in relation to renaming Herzog Park set to be withdrawn
- Russia downs 16 drones heading for Moscow, mayor says
- Track down the Ideal Weight reduction Methodology for Your Way of life
